Today: 11 June 2026
SoFi stock falls after-hours as Treasury yields tick up into year-end — what to watch next
1 January 2026
2 mins read

SoFi stock falls after-hours as Treasury yields tick up into year-end — what to watch next

NEW YORK, December 31, 2025, 17:57 ET — After-hours

  • SoFi shares were down about 1.4% in after-hours trading on the final U.S. session of 2025.
  • A late-year rise in Treasury yields weighed on rate-sensitive fintech and consumer-lending names.
  • Investors are watching the 2026 rate path and SoFi’s next earnings update.

SoFi Technologies, Inc. shares fell in after-hours trading on Wednesday, extending a year-end pullback for rate-sensitive fintech stocks. The stock was down 1.4% at $26.18, after trading between $26.08 and $26.90 with about 33.8 million shares changing hands.

The selloff came as U.S. borrowing costs moved higher, a key variable for consumer lenders. The 10-year Treasury yield rose 3.5 basis points — one basis point is 0.01 percentage point — to 4.163% after jobless-claims data showed an unexpected dip in applications for unemployment benefits, a Reuters report said.

Year-end funding conditions were also in focus after the Federal Reserve Bank of New York said firms borrowed a record $74.6 billion from its Standing Repo Facility, a backstop where the Fed lends cash against securities. “The funding market is more secure, there’s less panic, and more confidence that the SRF is working,” said Scott Skyrm, a money market trader at Curvature Securities. Reuters

Other fintech lenders and consumer-credit names were also lower. Affirm fell about 1.8%, Upstart dropped roughly 2.7% and LendingClub was down about 1.7% in after-hours trading.

The broader market ended the year with modest declines as holiday-thinned trading reduced conviction. The S&P 500 fell 0.74% on Wednesday and the Nasdaq slid 0.76%, Reuters reported.

SoFi, which runs a consumer-facing digital bank and lending franchise, often trades like a high-beta stock — meaning it tends to swing more than the broader market. Shifts in yields can pressure valuations for growth stocks and ripple through funding costs and refinancing demand across consumer credit.

The company is also still digesting the impact of a $1.5 billion common-stock offering completed earlier this month, an SEC filing showed. Equity offerings increase share count, which can dilute earnings per share if profits do not rise fast enough.

SoFi last lifted its 2025 profit forecast after reporting a record quarter in late October, Reuters reported. Investors have since focused on whether the company can sustain growth in lending and fee-based businesses as the rate outlook shifts.

Looking into 2026, traders expect fewer Federal Reserve rate cuts than in 2025, with markets pricing about 60 basis points of easing next year as of Monday, according to a Reuters report. That matters for SoFi’s net interest margin — the spread between what it earns on loans and pays on deposits and other funding.

The next major company catalyst is its fourth-quarter earnings report, which Nasdaq’s earnings calendar currently estimates for Jan. 26, 2026. The date can shift until SoFi confirms a schedule.

Investors will be listening for updates on credit performance, loan growth and deposit trends, alongside any commentary on demand as consumers move into 2026. Traders will also keep one eye on Treasury yields and money-market rates as year-end balance sheet pressures fade.

For now, SoFi shares look set to trade with the market’s appetite for rate-sensitive growth stocks, keeping macro data and the Fed’s 2026 message in the driver’s seat.

Stock Market Today

  • Cerebras Systems Shares Rise 4.64% on Morgan Stanley Buy Rating
    June 10, 2026, 10:46 PM EDT. Cerebras Systems Inc. (NASDAQ:CBRS) gained 4.64% to close at $237.33 after Morgan Stanley issued a buy rating and set a $250 price target, signaling a 5% upside. The investment bank highlighted Cerebras as a standout in AI infrastructure, with a unique position in low-latency inference hardware-a growing market segment. The company, listed on May 14 at $185, has already surged 28%. Morgan Stanley cited a strong contracted backlog of 750 MW capacity agreements supporting future growth. Despite CBRS's momentum, some investors may find other AI stocks more attractive due to greater upside or lower risk profiles.

Latest articles

Tech stocks slide after hours, Oracle’s AI spending draws focus

Tech stocks slide after hours, Oracle’s AI spending draws focus

11 June 2026
Semiconductor stocks plunged 3.6%, dragging the S&P 500 technology sector into correction territory—down 11% from its June 2 record—as investors punished AI-linked companies like Oracle and Super Micro Computer for heavy spending and capital raises, signaling a shift in risk appetite amid rising inflation and escalating U.S.-Iran tensions.
Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

11 June 2026
Murphy USA soared 10.04% to $612.16 as investors seized on Casey’s General Stores’ stronger-than-expected fuel margins, spotlighting sector-wide pump profitability; with Murphy’s own first-quarter fuel contribution up 40.6% and margins at 35.0 cents per gallon, the stock’s jump reflects bets that high margins will persist, though volatility in fuel prices remains a key risk.
Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

11 June 2026
Sky Quarry soared 22.44% to $1.91 on record volume, then jumped to $2.38 after hours, as investors bet on a June refinery restart after repairs and a feedstock shortage crushed Q1 revenue to $383; with just $66,828 in cash and “substantial doubt” about its ability to continue, the stock’s fate hinges on hitting its June production target.
Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading
Previous Story

Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop